Ernexa Therapeutics Selected for Prestigious JETRO Japan Entry Acceleration Program

Ernexa Therapeutics, a biotech firm, has been selected as one of ten global companies to participate in JETRO's Japan Entry Acceleration Program. The program aims to foster collaboration between international innovators and Japanese companies in the regenerative medicine sector. Ernexa's participation will help advance its pipeline in Japan, where it is developing cell therapies for cancer and autoimmune diseases. The program will provide expert-led mentoring and market-entry guidance, as well as opportunities to engage with Japanese research and development organizations.